Sensitive detection of somatic mutations in GC-rich cancer gene promoters.
Summary
Somatic mutations in GC-rich promoter regions are significant drivers of cancer, yet their detection is challenging due to poor sequencing coverage in these areas. This study introduces a hybrid capture assay optimized for over 3000 cancer gene promoters, enabling deep sequencing of these complex regions. This method facilitates the discovery of reliable point mutations, short insertions/deletions, copy number variants, and mutational signatures. The assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer, paving the way for future functional follow-up.
Analysis
This advancement is crucial for translational research and clinical practice as it solves a major technical challenge in identifying somatic mutations within promoter regions. By enabling sensitive detection of these alterations in previously difficult-to-analyze areas, it opens new avenues for understanding cancer initiation and progression mechanisms. The ability to identify novel biomarkers and potential therapeutic targets, such as those found in breast cancer, could lead to more precise diagnostics and the development of more effective therapies, particularly for cancers with GC-rich promoters.